Prosecution Insights
Last updated: April 19, 2026

Examiner: SU-TOBON, QIWEN NMN

Tech Center 1600 • Art Units: 1636

This examiner grants 0% of resolved cases

Performance Statistics

%
Allow Rate
-60.0% vs TC avg
20
Total Applications
Interview Lift
1175
Avg Prosecution Days
Based on 0 resolved cases, 2023–2026

Rejection Statute Breakdown

6.9%
§101 Eligibility
10.3%
§102 Novelty
44.8%
§103 Obviousness
21.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18296350 METHODS FOR REGULATING BLOOD-CENTRAL NERVOUS SYSTEM (BLOOD-CNS) BARRIER AND USES THEREOF Non-Final OA President and Fellows of Harvard College
17800417 COMPOSITIONS AND METHODS FOR IDENTIFYING HOST CELL TARGET PROTEINS FOR TREATING RNA VIRUS INFECTIONS Non-Final OA The Regents of the University of California
17849132 METHODS AND COMPOSITIONS FOR INHIBITING CORONAVIRAL REPLICATION Non-Final OA California Institute of Technology
18032868 REPROGRAMMABLE ISCB NUCLEASES AND USES THEREOF Non-Final OA MASSACHUSETTS INSTITUTE OF TECHNOLOGY
18030324 T-DNA MEDIATED GENETIC MODIFICATION Non-Final OA MASSACHUSETTS INSTITUTE OF TECHNOLOGY
18330563 SUMO Targeting Morpholinos as both Enhancers of Anti-Cancer Effects of Chemotherapeutic Treatments and Preventative Agents Against the Establishment of Chemoresistance Non-Final OA Board of Regents, The University of Texas System
18814161 Deaminase-Based RNA Sensors Non-Final OA The Board of Trustees of the Leland Stanford Junior University
18276163 METHODS FOR MANUFACTURING A SYNTHETIC TEMPLATE Non-Final OA Nutcracker Therapeutics, Inc.
18262792 PREVENTIVE OR THERAPEUTIC AGENT FOR BENIGN ADULT FAMILIAL MYOCLONIC EPILEPSY Non-Final OA RIKEN
18547930 METHOD FOR DECREASING DEGENERATION OF RETINAL GANGLION CELLS Non-Final OA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
16838960 GENOMIC SEQUENCE MODIFICATION METHOD FOR SPECIFICALLY CONVERTING NUCLEIC ACID BASES OF TARGETED DNA SEQUENCE, AND MOLECULAR COMPLEX FOR USE IN SAME Non-Final OA NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
17613387 COMPOSITIONS AND METHODS FOR CD33 MODIFICATION Non-Final OA VOR BIOPHARMA INC.
18050511 LACTIC ACID BACTERIA HAVING IMPROVED SUGAR METABOLISM Final Rejection DUPONT NUTRITION BIOSCIENCES APS
18028865 IDENTIFICATION OF PAX3-FOXO1 BINDING GENOMIC REGIONS Non-Final OA The Research Institute at Nationwide Children's Hospital
18189783 EXPRESSION VECTOR FOR USE IN METHANOTROPH Non-Final OA KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
18546024 METHODS AND SYSTEMS FOR GENERATING NUCLEIC ACID DIVERSITY Non-Final OA Institut Pasteur
18022968 VECTOR-FREE PROCESS FOR MANUFACTURE OF ENGINEERED IMMUNE CELLS Non-Final OA Tmunity Therapeutics Inc.
17836304 Nucleic Acid Carriers And Therapeutic Methods Of Use Non-Final OA Code Biotherapeutics, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month